Details of the Drug

General Information of Drug (ID: DM4OHMP)

Drug Name
A-3309
Synonyms
Elobixibat; ALBI-3309; Ileal bile acid transporter inhibitors, AstraZeneca; ASBT inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitor (oral, chronic idiopathic constipation), Albireo; Apical sodium-dependent bile acid transporter inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitors (1,5-benzothiazepine derivatives), AstraZeneca
Indication
Disease Entry ICD 11 Status REF
Lipid metabolism disorder 5C52.Z Phase 3 [1]
Structure
3D MOL 2D MOL
Cross-matching ID
PubChem CID
9939892
TTD ID
D04BLE
VARIDT ID
DR00525

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ileal sodium/bile acid cotransporter (SLC10A2) TTPI1M5 NTCP2_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Lipid metabolism disorder
ICD Disease Classification 5C52.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ileal sodium/bile acid cotransporter (SLC10A2) DTT SLC10A2 2.54E-01 -0.06 -0.17
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01895543) Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation. U.S. National Institutes of Health.
2 Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84.